Hepatoprotective Strategies Against Ischemia-Reperfusion Injury

While options for managing IRI in liver diseases are limited, several treatments have emerged that effectively protect hepatocytes. Trimetazidine in the IGL-1 solution inhibits p53 and activates SIRT1, thus protecting hepatocytes from IRI (Pantazi et al., 2015b (link)). Rebamipide reduces inflammation and improves histological alterations in the liver, crucial for recovery post-reperfusion, which increases SIRT1 expression and modulatesβ-catenin and FOXO1, while suppressing NF- κB p65 expression (Gendy, Abdallah & El-Abhar, 2017 (link); Elwany et al., 2023 (link)). Losartan mitigates liver injury associated with transplantation, improving overall transplantation success rates via SIRT1, enhancing the liver’s defense against oxidative stress and inflammation (Pantazi et al., 2015a (link)). Tauroursodeoxycholic acid modulates the SIRT1/FXR signaling pathway beneficial in managing IRI during liver surgeries (Sun et al., 2020 (link)). Pachymic acid maintains SIRT1 expression during oxygen-glucose deprivation/reoxygenation (Xue et al., 2023a (link); Xue et al., 2023b (link)).